AURA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-11

• We believe bel-sar has the possibility to transform the field of ocular oncology beyond choroidal melanoma and we are expanding clinical development in two additional indications: metastases to the choroid and cancers of the ocular surface. We continue to enroll patients in an ongoing Phase 2 clinic…

• Beyond ocular cancers, bel-sar is in clinical development in bladder cancer. Bladder cancer is the ninth most common cancer worldwide and the majority of cases are diagnosed early as non-muscle invasive bladder cancer, or NMIBC, with a prevalence of approximately 80,000 cases per year in the United …

• General and administrative expenses increased to $6.9 million for the three months ended March 31, 2026 from $5.7 million for the three months ended March 31, 2025, primarily driven by higher personnel expenses related to growth of our company and increased professional fees.

• To date we have funded our operations primarily through the sale of convertible preferred stock, warrants and common stock. Through May 5, 2026, we have raised an aggregate of approximately $797.8 million of gross proceeds primarily from private placements of our equity and convertible preferred sto…

• During the three months ended March 31, 2026, net cash used in operating activities was $29.9 million primarily due to our net loss of $33.7 million and a decrease in accrued expenses and other current liabilities related to timing of vendor invoicing and payments, partially offset by stock-based co…

Text removed vs the prior filing · source: 10-Q · 2025-11-13

• We believe bel-sar has the possibility to transform the field of ocular oncology beyond choroidal melanoma and we plan to expand clinical development in two additional indications: metastases to the choroid and cancers of the ocular surface. Bel-sar has the potential to treat a wide variety of tumor…

• Beyond ocular cancers, bel-sar is in early clinical development in bladder cancer. Bladder cancer is the ninth most common cancer worldwide and it is diagnosed early as non-muscle invasive bladder cancer, or NMIBC, with a prevalence of approximately 80,000 cases per year in the United States. Despit…

• General and administrative expenses decreased to $5.7 million for the three months ended September 30, 2025 from $6.2 million for the three months ended September 30, 2024, primarily driven by reduced professional fees.

• Comparison of the Nine Months Ended September 30, 2025 and 2024

• The following table summarizes our results of operations for the nine months ended September 30, 2025 and 2024:

Text added vs the prior filing · source: 10-Q · 2026-05-11

• changes to manufacturing costs or processes implemented by third-party manufacturers; and

• Furthermore, developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidate. We may not be able to build an effective sales and marketing organization

• in the United States, the EU or other key global markets. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidate, we may have difficulties generating revenue from them.

• The rules dealing with the U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application), inc…

• It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders’ tax liability or require chang…

Text removed vs the prior filing · source: 10-Q · 2025-11-13

• Furthermore, developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidate. We may not be able to build an effective sales and marketing organization in the United States, the EU or other key global markets. If we…

• The rules dealing with the U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application), inc…

• For example, recent legislation that was signed into law on July 4, 2025 made significant changes to U.S. federal tax law. Under Section 174 of the Internal Revenue Code of 1986, as amended, or the Code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and …

• the United States may, at the taxpayer’s election, be immediately deducted or capitalized and amortized. In addition, the new tax legislation provides that for taxable years beginning after December 31, 2021 and before January 1, 2025, certain eligible taxpayers generally may elect to retroactively …

• It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders’ tax liability or require chang…

Text added vs the prior filing · source: 10-Q · 2026-05-11

• As previously disclosed, on April 30, 2026, we and Matrix entered into a stock purchase agreement pursuant to which we agreed to repurchase, in a privately negotiated transaction, up to 6,922,870 shares of our common stock held by Matrix. On May 7, 2026, we completed the repurchase of all 6,922,870 …

• None of our directors or officers, as defined in Rule 16a-1(f) under the Securities Act, adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) of Regulation S-K, during the quarter ended March 31, 2026.

Text removed vs the prior filing · source: 10-Q · 2025-11-13

• None of our directors or officers, as defined in Rule 16a-1(f) under the Securities Act, adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) of Regulation S-K, during the quarter ended September 30, 2025.